Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

October 26, 2025

Study Completion Date

October 26, 2025

Conditions
Hidradenitis Suppurativa
Interventions
BIOLOGICAL

Injectable suspension of allogeneic adult mesenchymal stem cells

Cell therapy treatment will be administered in a single dose at the beginning of the study. The treatment consists of the administration of a single dose of allogeneic adult mesenchymal stem cells from adipose tissue. The dose is 120 million cells (drug volume: 20 ml, concentrated at 6 million cels/ml).

OTHER

Placebo

The placebo consists of the administration of the excipient of the suspension without cells. The excipient is a mixture of 50% hyaluronic acid, 49% DMEM without phenol red and 1% L-Alanine-L Glutamine.

Trial Locations (1)

18014

RECRUITING

Hospital Universitario Virgen de Las Nieves, Granada

All Listed Sponsors
lead

Andalusian Network for Design and Translation of Advanced Therapies

OTHER